Skip to search formSkip to main contentSkip to account menu

Dihydroergotamine

Known as: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide, 9,10-dihydroergotamine, Dihydroergotamin 
A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
In a randomized double-blind study of 660 patients with predominantly abdominal-surgical procedures the thrombosis-preventing… 
2004
2004
SummaryThe effect of dihydroergotamine on superficial veins of the hand has been investigated in healthy volunteers. The… 
1995
1995
Mission statement. The Quality Standards Subcommittee CQSS) will seek to develop scientifically sound and clinically relevant… 
1980
1980
Changes in tension were monitored isometrically on spiral strips from canine saphenous and femoral veins. Dihydroergotamine… 
1977
1977
2136 patients in general surgery, gynaecology and urology were investigated by the 125I-fibrinogen-uptake-test for detection of… 
1969
1969
Summary The usual reduction in the concentration of plasma free fatty acids (FF A) caused by a single intravenous injcction of… 
1961
1961
The mechanism of morphine hyperglycemia was studied in intact and chronically adrenalectomized dogs. Adrenergic blocking agents… 
1959